Navigation Links
Nycomed's Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Date:10/28/2008

- Both 12-month pivotal studies in patients with symptomatic Chronic Obstructive Pulmonary Disease (COPD) meet primary endpoints

- Data show reductions in moderate and severe exacerbations requiring medical intervention

- Application for marketing authorisation in EU and US expected in 2009

- Partnering process for commercialisation in the US to be initiated

ZURICH, Switzerland, Oct. 28 /PRNewswire/ -- Nycomed today announced encouraging results from a preliminary analysis of four Phase III trials of Daxas(R) (roflumilast) in the treatment of symptomatic COPD. Two pivotal 12-month studies met their primary endpoints, showing effects on exacerbation rates and pulmonary function (FEV1). Furthermore, two supporting six-month studies confirmed the efficacy of Daxas when used with standard bronchodilator treatments. Further analysis including the secondary endpoints is ongoing and full data from all four studies are expected to be published during 2009. In light of the initial data analysis, Nycomed expects to file for European and US marketing authorisation next year. The company will also initiate the process of identifying a partner to commercialise Daxas in the United States.

Commenting on today's announcement, Hakan Bjorklund, Chief Executive Officer of Nycomed, said: "We are extremely encouraged by the positive results from our preliminary analysis of four phase III trials involving more than 4,500 patients. We believe Daxas has the potential to make a significant contribution to COPD management and will therefore be a great addition to Nycomed's product portfolio."

Anders Ullman, Executive Vice President R&D, added: "COPD has a very high morbidity and mortality. Epidemiological data suggest that it is growing at a significant rate all around the world. Daxas is well placed to be the only anti-inflammatory product that specifically targets the inflammatory processes, which appear to play an important role in COPD. Wi
'/>"/>

SOURCE Nycomed
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Jellyfish Protein Shows Potential to Help With Memory
2. Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents
3. New carbon material shows promise of storing large quantities of renewable electrical energy
4. Oil palm plantations are no substitute for tropical rainforests, a new study shows
5. Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures
6. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
7. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
8. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
9. Atrium shows a strong financial performance for its first quarter
10. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
11. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2010)... agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). , ... ... ... ... PRIALT is ...
(Date:3/11/2010)... 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative ... with University Health Network (UHN) and The Hospital for Sick Children (SickKids) in ... programs in the areas of hematopoietic stem cell transplantation and cancer. , ... ... ...
(Date:3/10/2010)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be ... ... , ... ... ...
(Date:3/10/2010)... a company developing products for the treatment of sepsis, today announced the appointment of Mr. Kevin Giese , President, CEO and Director of BioMS Medical ... ... , , ... ... ...
Breaking Biology Technology:Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference 2Spectral appoints two new board members 2Spectral appoints two new board members 3
... Headquarters in Wilmington. , ... Wilmington, ... leaders today unveiled their $80 million Innovation Center partnership, the ... Delaware. The partnership includes opening of the DuPont Innovation ...
... CITY, New Jersey, October 23, Rosetta Genomics Ltd. ... microRNA-based diagnostics and therapeutics, today,announced that it will ... Markers in Cancer". The event will take place ... The poster presentation, titled "MicroRNA-based identification of ...
... 27, 2009 to Regain Compliance with $1.00 ... Minimum Bid Price ... PPHM ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ... has received a letter,from NASDAQ that provides Peregrine with additional time ...
Other Biology Technology:DuPont and State of Delaware Unveil $80 Million Innovation Center Partnership 2DuPont and State of Delaware Unveil $80 Million Innovation Center Partnership 3DuPont and State of Delaware Unveil $80 Million Innovation Center Partnership 4DuPont and State of Delaware Unveil $80 Million Innovation Center Partnership 5Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 2Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 3Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule 2
(Date:3/12/2010)... a vital factor in modern viticulture, due to the ... wine quality and the environmental impact of agricultural practices ... area, the NEIKER-Tecnalia technological centre is carrying out research ... irrigation regimes for the typical flat and sloping soils ... grape and wine quality. The initial results when cover ...
(Date:3/11/2010)... a molecular image of a system that moves electrons ... for biology and could provide insights to minimize energy ... electricity around the country. , The research, led ... of Biological Sciences, is published in the March 12 ... has been fine-tuning electricity in organisms for a lot ...
(Date:3/11/2010)... the gun to better manage their disease by controlling ... the sticky wicket of needing treatment that makes them ... sugar levels and prevent weight gain may suggest an ... to blame, said Dr. Deborah Young-Hyman, pediatric psychologist at ... , "You can,t use the same criteria to diagnose ...
Breaking Biology News(10 mins):The use of cover crops in vineyards can help control the yield and quality of grapes and wine 2The use of cover crops in vineyards can help control the yield and quality of grapes and wine 3U of Minnesota researcher discovers how electricity moves through cells 2Diabetes' link to eating disorders explored 2Diabetes' link to eating disorders explored 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel 28R 29 7576 1Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel 28R 29 7576 2Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel 28R 29 7576 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel 28R 29 7576 4Chinas Basic Medical Insurance to Cover Sinobiopharmas Flagship Product 7574 1Chinas Basic Medical Insurance to Cover Sinobiopharmas Flagship Product 7574 2Chinas Basic Medical Insurance to Cover Sinobiopharmas Flagship Product 7574 3Long Before Symptoms Blood May Reveal Rheumatoid Arthritis 65556 1Long Before Symptoms Blood May Reveal Rheumatoid Arthritis 65556 2
... HIV screening can increase patient life span, prevent the spread ... Harvard and the Massachusetts General Hospital report in the February ... , The study's findings are part of a two-paper series ... the United States. The Yale/Harvard study used different data and ...
... developed a novel method to simultaneously control the size ... pharmaceutical synthesis and novel biomedical applications. , This groundbreaking ... Angewandte Chemie, and a United States patent has been ... Han and IBN Executive Director Prof. Jackie Y. Ying ...
... scientists at the University of St Andrews have developed ... laser light. The new technique, which is cheap and ... biomedicine and healthcare. , Optical technology has huge potential ... Andrews has outstanding research groups in this area. The ...
Other Biology News:Boosting HIV screening can increase survival and is cost effective 2Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications 2New methods of gene delivery using lasers 2
... peptide whose sequences are derived from mouse resistin protein. The ... S - M - P - L - C - P ... D - K - K - I - K - Q ... for neutralization and control experiments with the polyclonal antibody that reacts ...
... Custom peptide microarrays designed for quantitative ... samples and built on the flexible ... Thousands of customer specified sequences can ... can provide assistance with custom sequence ...
... a 16 amino acid (amino acids 3-18) synthetic peptide whose ... sequence of this peptide is (amino to carboxy terminus): Q(3) ... - K - L - R - A - L ... This peptide may be used for neutralization and ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
Biology Products: